2. Search Result
Search Result
Results for "

Ruxolitinib

" in MedChemExpress (MCE) Product Catalog:

15

阻害剤およびアゴニスト

6

同位体標識化合物

製品番号 製品名 Target 研究分野 構造式
  • HY-50856
    Ruxolitinib
    Maximum Cited Publications
    259 Publications Verification

    INCB18424

    		 JAK Autophagy Mitophagy Apoptosis Cancer
    Ruxolitinib (INCB18424) is an orally active and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3 . Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy .
    Ruxolitinib
  • HY-50858
    Ruxolitinib phosphate
    Maximum Cited Publications
    259 Publications Verification

    INCB018424 phosphate

    		 JAK Autophagy Mitophagy Cancer
    Ruxolitinib phosphate (INCB018424 phosphate) is a potent JAK1/2 inhibitor with IC50s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.
    Ruxolitinib phosphate
  • HY-50856A
    Ruxolitinib (S enantiomer)
    3 Publications Verification

    S-Ruxolitinib; S-INCB18424

    		 JAK Cancer
    Ruxolitinib (S enantiomer) (S-Ruxolitinib) is the S-enantiomer of Ruxolitinib (HY-50856). Ruxolitinib (S enantiomer) is an orally active, potent JAK inhibitor .
    Ruxolitinib (S enantiomer)
  • HY-50856S
    Deuruxolitinib

    CTP-543; Ruxolitinib d8; Deuterated Ruxolitinib

    		 JAK Inflammation/Immunology
    Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), is an orally active JAK1 and JAK2 inhibitor. Deuruxolitinib demonstrates significant hair regrowth effects. Deuruxolitinib can be used for the research of alopecia areata .
    Deuruxolitinib
  • HY-50856R
    Ruxolitinib (Standard)

    INCB18424 (Standard)

    		 Reference Standards JAK Autophagy Mitophagy Apoptosis Cancer
    Ruxolitinib (Standard) is the analytical standard of Ruxolitinib. This product is intended for research and analytical applications. Ruxolitinib (INCB18424) is a potent and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3 . Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy .
    Ruxolitinib (Standard)
  • HY-151902
    SJ988497

    		PROTACs JAK Cancer
    SJ988497 is a PROTAC JAK2 degrader. SJ988497 potently inhibits CRLF2-rearranged (CRLF2r) cell proliferation and degrades the CRBN neosubstrate GSPT1. SJ988497 consists of a Ruxolitinib (HY-50856) derivative, linker, and CRBN ligand Pomalidomide. SJ988497 can be used in the research of acute lymphoblastic leukemia (ALL) .
    SJ988497
  • HY-W062703S
    (Rac)-Ruxolitinib-d9

    (Rac)-INCB18424-d9; Ruxotinib racemate-d9

    		 Isotope-Labeled Compounds JAK Cancer
    (Rac)-Ruxolitinib D9 ((Rac)-INCB18424 D9) is the deuterium labeled (Rac)-Ruxolitinib. (Rac)-Ruxolitinib is a JAK2 inhibitor .
    (Rac)-Ruxolitinib-d9
  • HY-W062703S1
    (Rac)-Ruxolitinib-d8

    (Rac)-INCB18424-d8; Ruxotinib racemate-d8

    		 Isotope-Labeled Compounds Others
    (Rac)-Ruxolitinib-d8 is deuterium labeled (Rac)-Ruxolitinib.
    (Rac)-Ruxolitinib-d8
  • HY-W059210
    Ruxolitinib impurity-1

    		Biochemical Assay Reagents Others
    Ruxolitinib impurity-1 is the impurity of Ruxolitinib (HY-50856), which can be used safety analysis of Ruxolitinib therapy .
    Ruxolitinib impurity-1
  • HY-50859
    Ruxolitinib sulfate

    INCB018424 sulfate

    		 JAK Autophagy Cancer
    Ruxolitinib sulfate (INCB018424 sulfate) is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC50s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3.
    Ruxolitinib sulfate
  • HY-50856S2
    Ruxolitinib-d9

    INCB18424-d9

    		 Isotope-Labeled Compounds Apoptosis JAK Autophagy Mitophagy Cancer
    Ruxolitinib-d9 (INCB18424-d9) is deuterium labeled Ruxolitinib. Ruxolitinib (INCB18424) is an orally active and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3 . Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy .
    Ruxolitinib-d9
  • HY-159917
    PPL agonist-1

    		Tyrosinase Microtubule/Tubulin Inflammation/Immunology
    PPL agonist-1 is a highly selective Periplakin (PPL) agonist that increases cAMP levels by regulating PPL, thereby enhancing MITF expression and promoting melanin synthesis. Furthermore, PPL agonist-1 facilitates melanin production by regulating tryptophan metabolism. Compared to Ruxolitinib (HY-50856), PPL agonist-1 demonstrates superior efficacy. PPL agonist-1 holds potential for research into vitiligo treatment .
    PPL agonist-1
  • HY-Z18070S
    Ruxolitinib M18 metabolite impurity-d4

    		Isotope-Labeled Compounds Others
    Ruxolitinib M18 metabolite impurity-d4 is the deuterium labeled Ruxolitinib M18 metabolite impurity.
    Ruxolitinib M18 metabolite impurity-d4
  • HY-Z18070AS
    (Rac)-Ruxolitinib M18 metabolite impurity-d4

    		Isotope-Labeled Compounds Others
    (Rac)-Ruxolitinib M18 metabolite impurity-d4 is the deuterium labeled (Rac)-Ruxolitinib M18 metabolite impurity.
    (Rac)-Ruxolitinib M18 metabolite impurity-d4
  • HY-180561
    WWQ-03-012

    		Deubiquitinase JAK STAT Apoptosis Cancer
    WWQ-03-012 is a selective deSUMOylating isopeptidases DESI2 inhibitor with an IC50 of 47.3 μM. WWQ-03-012 cans induce JAK2-V617F ubiquitination-proteasome degradation with no significant effect on wild-type JAK2. WWQ-03-012 can block JAK2-STAT3/5 signaling, inhibit cell proliferation and induce apoptosis. WWQ-03-012 has a synergistic effect in combination with Ruxolitinib (HY-50856), further enhancing its killing effect on JAK2 mutant cells. WWQ-03-012 can be used for the research of cancer, such as myeloproliferative neoplasms .
    WWQ-03-012

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

タイトル

  

国或いは地域 *

お名前 *

 

組纖名 *

デパートメント *

     

メールアドレス *

 

製品名 *

製品番号

  

カスタマ需要量 *

電話番号 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: